Add this topic to your myFT Digest for news straight to your inbox
A population equivalent in size to Greater Manchester is not working due to ill health, at a huge and avoidable cost
Report from Nuffield Trust health think-tank highlights impact of leaving EU on medicine supply chains
Research harnesses power of generative artificial intelligence in latest sign of its potential use in medicine
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Almost 60 Conservatives oppose bill to stop anyone born after 2009 from ever being sold cigarettes legally
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
Official data shows health service missing key targets ahead of election expected this year
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
PM’s intervention comes after report finds ‘remarkably weak evidence’ surrounding medical interventions
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
GQG Partners argues that pharma group has performed strongly under long-serving chief
The generics sector is not getting the boost it needs from government
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
UK research highlights risk of over-diagnosis and gaps in spotting serious variants of the disease
The idea that the technology might accelerate general human capabilities remains fanciful
The rights of the terminally ill to choose a better death need careful consideration
Sector’s biggest company says it is talking to exchanges in London and Frankfurt
US healthcare company is putting cash to work from spinning off its consumer health arm
Research forecasts global deaths from the disease will almost double in 20 years
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
International Edition